litlas
Log inCreate account

Peter J. Goadsby

Active 1982–2025

Also published as
Peter J Goadsby
432
Papers
78,660
Citations
146
h-index
417
i10-index

Citations

Citations per year for Peter J. Goadsby1985: 1 citations1986: 2 citations1987: 2 citations1988: 6 citations1989: 9 citations1990: 12 citations1991: 21 citations1992: 20 citations1993: 41 citations1994: 43 citations1995: 52 citations1996: 60 citations1997: 135 citations1998: 79 citations1999: 118 citations2000: 121 citations2001: 178 citations2002: 256 citations2003: 273 citations2004: 417 citations2005: 400 citations2006: 493 citations2007: 419 citations2008: 531 citations2009: 742 citations2010: 551 citations2011: 456 citations2012: 466 citations2013: 554 citations2014: 460 citations2015: 435 citations2016: 392 citations2017: 663 citations2018: 609 citations2019: 2,158 citations2020: 2,180 citations2021: 2,101 citations2022: 1,791 citations2023: 1,588 citations2024: 2,510 citations2025: 1,161 citations2026: 24 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,011 citing papers, 24.7% of this breakdownUnited Kingdom: 1,076 citing papers, 8.8% of this breakdownItaly: 921 citing papers, 7.5% of this breakdownGermany: 791 citing papers, 6.5% of this breakdownDenmark: 604 citing papers, 4.9% of this breakdownChina: 598 citing papers, 4.9% of this breakdownSpain: 413 citing papers, 3.4% of this breakdownNetherlands: 386 citing papers, 3.2% of this breakdownCanada: 315 citing papers, 2.6% of this breakdownFrance: 279 citing papers, 2.3% of this breakdownAustralia: 257 citing papers, 2.1% of this breakdownSwitzerland: 224 citing papers, 1.8% of this breakdown
0%24.7%Other 27.3%

Institutions

Fields

  • Medicine82.7%
  • Neuroscience11%
  • Biochemistry, Genetics and Molecular Biology2.4%
  • Psychology0.9%
  • Pharmacology, Toxicology and Pharmaceutics0.7%
  • Health Professions0.7%
  • Other1.6%

Topics

  • Migraine and Headache Studies24%
  • Trigeminal Neuralgia and Treatments6.6%
  • Neurological Complications and Syndromes4.1%
  • Sympathectomy and Hyperhidrosis Treatments3%
  • Traumatic Brain Injury Research2.9%
  • Vestibular and auditory disorders2.8%
  • Other56.6%

Coauthors

All papers

Open in search
  1. Pathophysiology of Migraine: A Disorder of Sensory Processing

    Authors: Peter J. Goadsby, Philip R. Holland, Margarida Martins-Oliveira, Jan Hoffmann, Christoph J. Schankin, Simon Akerman - Physiological Reviews 2017 cited by 1,968

  2. Migraine

    Authors: Michel D. Ferrari, Peter J. Goadsby, Rami Burstein, Tobias Kurth, Cenk Ayata, Andrew Charles, Messoud Ashina, Arn M. J. M. van den Maagdenberg, David W. Dodick - Nature Reviews Disease Primers 2022 cited by 522

  3. Atogepant for the Preventive Treatment of Migraine

    Authors: Jessica Ailani, Richard B. Lipton, Peter J. Goadsby, Hua Guo, Rosa Miceli, Lawrence Severt, Michelle Finnegan, Joel M. Trugman - New England Journal of Medicine 2021 cited by 310

  4. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

    Authors: Robert Croop, Richard B. Lipton, David Kudrow, David Stock, Lisa Kamen, Charles M. Conway, Elyse Stock, Vladimir Coric, Peter J. Goadsby - The Lancet 2020 cited by 351

  5. A Controlled Trial of Erenumab for Episodic Migraine

    Authors: Peter J. Goadsby, Uwe Reuter, Yngve Hallström, Gregor Broessner, Jo Bonner, Feng Zhang, Sandhya Sapra, Hernàn Picard, Daniel D. Mikol, Robert Lenz - New England Journal of Medicine 2017 cited by 948

  6. Migraine: disease characterisation, biomarkers, and precision medicine

    Authors: Messoud Ashina, Gisela M. Terwindt, Mohammad Al‐Mahdi Al‐Karagholi, Irene de Boer, Mi Ji Lee, Debbie L. Hay, Laura Schulte, Nouchine Hadjikhani, Alexandra J. Sinclair, Håkan Ashina, Todd J. Schwedt, Peter J. Goadsby - The Lancet 2021 cited by 370

  7. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

    Authors: Peter J. Goadsby, Lars Edvinsson, Rolf Ekman - Annals of Neurology 1990 cited by 1,610

  8. Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

    Authors: Richard B. Lipton, Robert Croop, Elyse Stock, David Stock, Beth Morris, Marianne Frost, Gene M. Dubowchik, Charles M. Conway, Vladimir Coric, Peter J. Goadsby - New England Journal of Medicine 2019 cited by 396

  9. Fremanezumab for the Preventive Treatment of Chronic Migraine

    Authors: Stephen D. Silberstein, David W. Dodick, Marcelo E. Bigal, Paul Yeung, Peter J. Goadsby, Tricia Blankenbiller, Melissa Grozinski‐Wolff, Ronghua Yang, Yuju Ma, Ernesto Aycardi - New England Journal of Medicine 2017 cited by 803

  10. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

    Authors: Robert Croop, Peter J. Goadsby, David Stock, Charles M. Conway, Micaela Forshaw, Elyse Stock, Vladimir Coric, Richard B. Lipton - The Lancet 2019 cited by 392

  11. Galcanezumab in chronic migraine

    Authors: Holland C. Detke, Peter J. Goadsby, Shufang Wang, Deborah I. Friedman, Katherine J. Selzler, Sheena K. Aurora - Neurology 2018 cited by 578

  12. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Patricia Pozo‐Rosich, Jessica Ailani, Messoud Ashina, Peter J. Goadsby, Richard B. Lipton, Uwe Reuter, Hua Guo, Brittany Schwefel, Kaifeng Lu, Ramesh Boinpally, Rosa Miceli, Rosa De Abreu Ferreira, Emily McCusker, Sung Yun Yu, Lawrence Severt, Michelle Finnegan, Joel M. Trugman - The Lancet 2023 cited by 133

  13. Efficacy and safety of eptinezumab in patients with chronic migraine

    Authors: Richard B. Lipton, Peter J. Goadsby, Jeff Smith, Barbara Schaeffler, David M. Biondi, Joe Hirman, Susan Pederson, Brent Allan, Roger Cady - Neurology 2020 cited by 392

  14. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial

    Authors: Richard B. Lipton, Robert Croop, David Stock, Jennifer Madonia, Micaela Forshaw, Meghan Lovegren, Linda Mosher, Vladimir Coric, Peter J. Goadsby - The Lancet Neurology 2023 cited by 145

  15. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine

    Authors: David W. Dodick, Stephen D. Silberstein, Marcelo E. Bigal, Paul Yeung, Peter J. Goadsby, Tricia Blankenbiller, Melissa Grozinski‐Wolff, Ronghua Yang, Yuju Ma, Ernesto Aycardi - JAMA 2018 cited by 573

  16. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats

    Authors: Peter J. Goadsby, Lars Edvinsson - Annals of Neurology 1993 cited by 1,162

  17. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial

    Authors: Peter J. Goadsby, David W. Dodick, Jessica Ailani, Joel M. Trugman, Michelle Finnegan, Kaifeng Lu, Armin Szegedi - The Lancet Neurology 2020 cited by 230

  18. Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update

    Authors: Andrew Charles, Kathleen B. Digre, Peter J. Goadsby, Matthew S. Robbins, Andrew D. Hershey, The American Headache Society - Headache The Journal of Head and Face Pain 2024 cited by 195

  19. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

    Authors: Uwe Reuter, Peter J. Goadsby, Michel Lantéri‐Minet, Shihua Wen, Peggy Hours-Zesiger, Michel D. Ferrari, Jan Klatt - The Lancet 2018 cited by 470

  20. Migraine: from pathophysiology to treatment

    Authors: Francesca Puledda, Elisa Silva, Kanokrat Suwanlaong, Peter J. Goadsby - Journal of Neurology 2023 cited by 178

  21. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA

    Authors: David W. Dodick, Peter J. Goadsby, Todd J. Schwedt, Richard B. Lipton, Chengcheng Liu, Kaifeng Lu, Sung Yun Yu, Lawrence Severt, Michelle Finnegan, Joel M. Trugman - The Lancet 2023 cited by 85

  22. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults

    Authors: Cristina Tassorelli, Hans‐Christoph Diener, David W. Dodick, Stephen D. Silberstein, Richard B. Lipton, Messoud Ashina, Werner J. Becker, Michel D. Ferrari, Peter J. Goadsby, Patricia Pozo‐Rosich, Shuu‐Jiun Wang - Cephalalgia 2018 cited by 385

  23. Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS)

    Authors: AM Blumenfeld, SF Varon, TK Wilcox, DC Buse, AK Kawata, AN Manack, Peter J. Goadsby, RB Lipton - Cephalalgia 2010 cited by 644

  24. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks

    Authors: Farooq Maniyar, Till Sprenger, Teshamae Monteith, Christoph J. Schankin, Peter J. Goadsby - Brain 2013 cited by 494